CERo Therapeutics (CERO) said Monday the US Food and Drug Administration has cleared its second investigational new drug application for CER-1236 for a phase 1 trial in advanced solid tumors, specifically non-small cell lung cancer and ovarian cancer.
"Following the launch of our AML trial, we are now starting a second clinical study of CER-1236 to evaluate its potential in solid tumors," said Chief Medical Officer Robert Sikorski. AML refers to acute myeloid leukemia.
The company said that recent results showed that CER-1236 treated ovarian cancer cells and didn't generate toxicity in mice.
Price: 0.76, Change: +0.01, Percent Change: +1.20
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。